Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularization. 1998

F M Baer, and P Theissen, and C A Schneider, and E Voth, and U Sechtem, and H Schicha, and E Erdmann
Klinik III für Innere Medizin, Universität zu Köln, Cologne, Germany. Frank.Baer@Uni-Koeln.de

OBJECTIVE This study sought to evaluate whether myocardial viability, as assessed by magnetic resonance imaging (MRI), reliably predicts postrevascularization left ventricular (LV) recovery. BACKGROUND Compared with positron emission tomographic findings, MRI has proved to be a reliable technique for the identification of residual myocardial viability. However, the predictive accuracy of MRI-assessed preserved end-diastolic wall thickness (DWT) and dobutamine-induced systolic wall thickening (SWT) for LV functional recovery has not yet been evaluated. METHODS Rest and low dose dobutamine MRI was performed in 43 patients with a chronic infarct (> or =4 months since ischemic event) and LV dysfunction who had undergone revascularization of the infarct-related vessel. On the basis of segmental evaluation of corresponding short-axis tomograms, infarct regions were graded viable by MRI if 1) DWT was > or =5.5 mm, and 2) dobutamine-induced SWT was > or =2 mm in > or =50% of dysfunctional segments related to the infarct region. Functional recovery was defined as SWT > or =2 mm in > or =50% of infarct-related segments at rest 4 to 6 months after successful revascularization. RESULTS Recovery of regional SWT could be observed in 27 (63%) of 43 patients. Comparison MRI grading before and after revascularization indicated that dobutamine-induced SWT was a better predictor of LV functional recovery (sensitivity 89%, specificity 94%) than was preserved DWT (sensitivity 92%, specificity 56%). Segments that remained akinetic after revascularization had significantly lower DWT (6.0+/-3.1 mm [n = 219] vs. 9.8+/-2.6 mm [n = 188], p < 0.001) than those with improved SWT. Left ventricular ejection fraction increased significantly in patients with dobutamine-induced SWT than in those with no contractile reserve (14+/-9% vs. 3+/-9%, p < 0.0002), and the magnitude of this increase was correlated with the number of dobutamine-responsive segments per infarct region (r = 0.68, p < 0.0001). CONCLUSIONS Quantitative assessment of dobutamine-induced SWT in chronic infarcts by MRI is a highly accurate predictor of LV functional recovery, and the presence of significantly reduced DWT reliably indicates irreversible myocardial damage. Therefore, dobutamine stress testing for the assessment of myocardial viability can be restricted to patients with preserved DWT.

UI MeSH Term Description Entries
D008279 Magnetic Resonance Imaging Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques. Chemical Shift Imaging,MR Tomography,MRI Scans,MRI, Functional,Magnetic Resonance Image,Magnetic Resonance Imaging, Functional,Magnetization Transfer Contrast Imaging,NMR Imaging,NMR Tomography,Tomography, NMR,Tomography, Proton Spin,fMRI,Functional Magnetic Resonance Imaging,Imaging, Chemical Shift,Proton Spin Tomography,Spin Echo Imaging,Steady-State Free Precession MRI,Tomography, MR,Zeugmatography,Chemical Shift Imagings,Echo Imaging, Spin,Echo Imagings, Spin,Functional MRI,Functional MRIs,Image, Magnetic Resonance,Imaging, Magnetic Resonance,Imaging, NMR,Imaging, Spin Echo,Imagings, Chemical Shift,Imagings, Spin Echo,MRI Scan,MRIs, Functional,Magnetic Resonance Images,Resonance Image, Magnetic,Scan, MRI,Scans, MRI,Shift Imaging, Chemical,Shift Imagings, Chemical,Spin Echo Imagings,Steady State Free Precession MRI
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D009204 Myocardial Revascularization The restoration of blood supply to the myocardium. (From Dorland, 28th ed) Internal Mammary Artery Implantation,Myocardial Revascularizations,Revascularization, Myocardial,Revascularizations, Myocardial
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic

Related Publications

F M Baer, and P Theissen, and C A Schneider, and E Voth, and U Sechtem, and H Schicha, and E Erdmann
March 2000, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
F M Baer, and P Theissen, and C A Schneider, and E Voth, and U Sechtem, and H Schicha, and E Erdmann
September 1997, Journal of the American College of Cardiology,
F M Baer, and P Theissen, and C A Schneider, and E Voth, and U Sechtem, and H Schicha, and E Erdmann
May 1995, Circulation,
F M Baer, and P Theissen, and C A Schneider, and E Voth, and U Sechtem, and H Schicha, and E Erdmann
November 1998, The American journal of cardiology,
F M Baer, and P Theissen, and C A Schneider, and E Voth, and U Sechtem, and H Schicha, and E Erdmann
May 2000, The American journal of cardiology,
F M Baer, and P Theissen, and C A Schneider, and E Voth, and U Sechtem, and H Schicha, and E Erdmann
June 2007, American journal of physiology. Heart and circulatory physiology,
F M Baer, and P Theissen, and C A Schneider, and E Voth, and U Sechtem, and H Schicha, and E Erdmann
August 1993, Circulation,
F M Baer, and P Theissen, and C A Schneider, and E Voth, and U Sechtem, and H Schicha, and E Erdmann
November 1994, American heart journal,
F M Baer, and P Theissen, and C A Schneider, and E Voth, and U Sechtem, and H Schicha, and E Erdmann
December 2001, European heart journal,
F M Baer, and P Theissen, and C A Schneider, and E Voth, and U Sechtem, and H Schicha, and E Erdmann
September 2003, Circulation,
Copied contents to your clipboard!